187 related articles for article (PubMed ID: 36307926)
1. The role of complement in glomerulonephritis-are novel therapies ready for prime time?
Cheung CK; Dormer JP; Barratt J
Nephrol Dial Transplant; 2023 Jul; 38(8):1789-1797. PubMed ID: 36307926
[TBL] [Abstract][Full Text] [Related]
2. Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: A Review.
Kant S; Kronbichler A; Sharma P; Geetha D
Am J Kidney Dis; 2022 Apr; 79(4):582-600. PubMed ID: 34508831
[TBL] [Abstract][Full Text] [Related]
3. Pathological spectrum of glomerular disease in patients with renal insufficiency: a single-center study in Northeastern China.
Chen L; Luodelete M; Dong C; Li B; Zhang W; Nie P; Liu J; Chen X; Luo P
Ren Fail; 2019 Nov; 41(1):473-480. PubMed ID: 31198075
[No Abstract] [Full Text] [Related]
4. What is new in therapy of glomerulonephritis in 2003/2004.
Hruby Z
Rocz Akad Med Bialymst; 2004; 49():166-9. PubMed ID: 15631335
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II Type 1 Receptor Antibodies Are Higher in Lupus Nephritis and Vasculitis than Other Glomerulonephritis Patients.
Szymczak M; Heidecke H; Żabińska M; Rukasz D; Wiśnicki K; Tukiendorf A; Krajewska M; Banasik M
Arch Immunol Ther Exp (Warsz); 2022 Sep; 70(1):23. PubMed ID: 36152104
[TBL] [Abstract][Full Text] [Related]
6. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
Rovin BH; Adler SG; Barratt J; Bridoux F; Burdge KA; Chan TM; Cook HT; Fervenza FC; Gibson KL; Glassock RJ; Jayne DRW; Jha V; Liew A; Liu ZH; Mejía-Vilet JM; Nester CM; Radhakrishnan J; Rave EM; Reich HN; Ronco P; Sanders JF; Sethi S; Suzuki Y; Tang SCW; Tesar V; Vivarelli M; Wetzels JFM; Lytvyn L; Craig JC; Tunnicliffe DJ; Howell M; Tonelli MA; Cheung M; Earley A; Floege J
Kidney Int; 2021 Oct; 100(4):753-779. PubMed ID: 34556300
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid factors and glomerulonephritis.
Miyazaki M; Endoh M; Suga T; Yano N; Kuramoto T; Matsumoto Y; Eguchi K; Yagame M; Miura M; Nomoto Y
Clin Exp Immunol; 1990 Aug; 81(2):250-5. PubMed ID: 2201469
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of Glomerular Disease in Southern Arizona: Review of 10-Year Renal Biopsy Data.
Murugapandian S; Mansour I; Hudeeb M; Hamed K; Hammode E; Bijin B; Daheshpour S; Thajudeen B; Kadambi P
Medicine (Baltimore); 2016 May; 95(18):e3633. PubMed ID: 27149502
[TBL] [Abstract][Full Text] [Related]
9. CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.
Mariani LH; Bomback AS; Canetta PA; Flessner MF; Helmuth M; Hladunewich MA; Hogan JJ; Kiryluk K; Nachman PH; Nast CC; Rheault MN; Rizk DV; Trachtman H; Wenderfer SE; Bowers C; Hill-Callahan P; Marasa M; Poulton CJ; Revell A; Vento S; Barisoni L; Cattran D; D'Agati V; Jennette JC; Klein JB; Laurin LP; Twombley K; Falk RJ; Gharavi AG; Gillespie BW; Gipson DS; Greenbaum LA; Holzman LB; Kretzler M; Robinson B; Smoyer WE; Guay-Woodford LM;
Am J Kidney Dis; 2019 Feb; 73(2):218-229. PubMed ID: 30420158
[TBL] [Abstract][Full Text] [Related]
10. Idiopathic non-lupus full-house nephropathy is associated with poor renal outcome.
Rijnink EC; Teng YK; Kraaij T; Wolterbeek R; Bruijn JA; Bajema IM
Nephrol Dial Transplant; 2017 Apr; 32(4):654-662. PubMed ID: 28340077
[TBL] [Abstract][Full Text] [Related]
11. Advances in the pathology of glomerular diseases.
Weening JJ; Ronco P; Remuzzi G
Contrib Nephrol; 2013; 181():12-21. PubMed ID: 23689563
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.
Anliker-Ort M; Dingemanse J; van den Anker J; Kaufmann P
Front Immunol; 2020; 11():599417. PubMed ID: 33362783
[TBL] [Abstract][Full Text] [Related]
13. The role of the alternative pathway of complement activation in glomerular diseases.
Łukawska E; Polcyn-Adamczak M; Niemir ZI
Clin Exp Med; 2018 Aug; 18(3):297-318. PubMed ID: 29450785
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of immunoglobulins and complements in formaldehyde-fixed and paraffin-embedded renal biopsy tissues; an adjunct for diagnosis of glomerulonephritis.
Chowdhury AR; Ehara T; Higuchi M; Hora K; Shigematsu H
Nephrology (Carlton); 2005 Jun; 10(3):298-304. PubMed ID: 15958046
[TBL] [Abstract][Full Text] [Related]
15. Complement Inhibitors in Clinical Trials for Glomerular Diseases.
Zipfel PF; Wiech T; Rudnick R; Afonso S; Person F; Skerka C
Front Immunol; 2019; 10():2166. PubMed ID: 31611870
[TBL] [Abstract][Full Text] [Related]
16. Glomerulonephritis Histopathological Pattern Change.
AlYousef A; AlSahow A; AlHelal B; Alqallaf A; Abdallah E; Abdellatif M; Nawar H; Elmahalawy R
BMC Nephrol; 2020 May; 21(1):186. PubMed ID: 32423387
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis and treatment of glomerulonephritis-an update.
Couser WG
J Bras Nefrol; 2016 Mar; 38(1):107-22. PubMed ID: 27049372
[TBL] [Abstract][Full Text] [Related]
18. New diagnostic tests and new therapies for glomerular diseases.
Appel GB; Appel AS
Blood Purif; 2013; 35(1-3):81-5. PubMed ID: 23343551
[TBL] [Abstract][Full Text] [Related]
19. A pilot and comparative study between pathological and serological levels of immunoglobulin and complement among three kinds of primary glomerulonephritis.
Dong J; Peng T; Gao J; Jia X; Yan G; Wang Y
BMC Immunol; 2018 Jun; 19(1):18. PubMed ID: 29925312
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pathological analysis of renal biopsies of elderly patients in Northeast China: a single-center study.
Nie P; Lou Y; Wang Y; Bai X; Zhang L; Jiang S; Li B; Luo P
Ren Fail; 2021 Dec; 43(1):851-859. PubMed ID: 33970769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
